Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) has released its Monthly Return for the period ended 30 September 2026, detailing the following key changes in its share capital structure:

1. Share Repurchases Between 1 and 30 September 2026, Weigao Group repurchased 3.08 million H-shares on the Hong Kong Stock Exchange. • Transaction volume: 3,075,200 shares, equivalent to 0.07 % of the 4.52 billion H-shares in issue at August month-end. • Purchase prices: lowest HKD 3.0859; highest HKD 3.3184 per share. • Resulting shift: issued shares (excluding treasury) fell to 4,456.11 million, while treasury shares grew to 66.22 million.

2. Authorised and Issued Share Capital • Total authorised share capital remained unchanged at RMB 457.06 million, split between 4.52 billion listed H-shares and 48.30 million unlisted shares, each with a par value of RMB 0.10. • No new shares, options, warrants or convertible securities were issued during the month.

3. Public Float Compliance Despite the increased treasury share balance, the company confirmed that it continues to meet the Hong Kong Main Board’s minimum 25 % public-float requirement as of 30 September 2026.

4. Governance Confirmation The board attested that all repurchase transactions were duly authorised and executed in compliance with Hong Kong listing rules and relevant regulations.

The September activity underscores Weigao Group’s ongoing share repurchase programme, with a modest reduction in outstanding H-shares and a corresponding build-up of treasury stock, while overall share capital and regulatory compliance remain intact.